JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report

被引:3
作者
Yhim, Ho-Young [1 ]
Kim, Hee Sun [4 ]
Sohn, Ji-Youn [1 ]
Song, Min-Ju [1 ]
Lee, Na-Ri [1 ,3 ]
Song, Eun-Kee [1 ,3 ]
Choi, Sam-Im [2 ]
Yim, Chang-Yeol [1 ,3 ]
Kwak, Jae-Yong [1 ,3 ]
机构
[1] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Div Hematol Oncol, Jeonju 561712, South Korea
[2] Chonbuk Natl Univ, Sch Med, Dept Lab Med, Jeonju 561712, South Korea
[3] Chonbuk Natl Univ, Sch Med, Adv Res Canc Ctr, Jeonju 561712, South Korea
[4] Jeonbuk Sci Coll, Dept Nursing, Jeongeup 580712, South Korea
关键词
TYROSINE KINASE JAK2; CANCER INCIDENCE; MYELOID METAPLASIA; MUTATION; MEN;
D O I
10.1016/j.cancergencyto.2010.01.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Klinefelter syndrome (KS) is the most commonly diagnosed X chromosome aneuploid syndrome among males. The association between hematologic malignancies such as non-Hodgkin lymphoma and leukemia and KS has been established recently on the basis of numerous case reports and a large cohort study. The risk of chronic myeloproliferative disease (MPD) as a hematologic malignancy in KS, however, has not been evaluated to date. Moreover, to our knowledge, there is only one case report that observed MPD in a patient with KS. Even though the Janus kinase 2 (JAK2) mutation was considered the primary cause in the pathogenesis of MPD, the mutation status was not described in that report. We found JAK2 V617F mutation-positive essential thromobocythemia (ET) in a patient with KS. To the best of our knowledge, this case represents the first case report of JAK2 V617F mutation in a patient with KS. Furthermore, we also suggest the hypothesis that X chromosome aneuploidy as a "pre-JAK2" cytogenetic change may be associated with the development of clonal hematopoiesis and carcinogenesis, because of the finding of higher oncogenic potential of extra X chromosome. In this study, we present the first report of JAK2 V617F-positive ET in a patient with KS, as well as a review of the relevant literature. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [41] Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F-and MPLW515 L-positive myelofibrosis
    Schulze, Susann
    Stengel, Rayk
    Jaekel, Nadja
    Wang, Song-Yau
    Franke, Georg-Nikolaus
    Roskos, Martin
    Schneider, Melanie
    Niederwieser, Dietger
    Al-Ali, Haifa Kathrin
    GENES CHROMOSOMES & CANCER, 2019, 58 (11) : 747 - 755
  • [42] Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia
    Shirane, Shuichi
    Araki, Marito
    Morishita, Soji
    Edahiro, Yoko
    Sunami, Yoshitaka
    Hironaka, Yumi
    Noguchi, Masaaki
    Koike, Michiaki
    Sato, Eriko
    Ohsaka, Akimichi
    Komatsu, Norio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (02) : 148 - 153
  • [43] JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients
    Coucelo, Margarida
    Caetano, Goncalo
    Sevivas, Teresa
    Santos, Susana Almeida
    Fidalgo, Teresa
    Bento, Celeste
    Fortuna, Manuela
    Duarte, Marta
    Menezes, Cristina
    Leticia Ribeiro, M.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (01) : 32 - 40
  • [44] JAK2 V617F, MPL W515L and JAK2 exon 12 mutations in Chinese patients with primary myelofibrosis
    Xia, Jun
    Lu, Mi-ze
    Jiang, Yuan-qiang
    Yang, Guo-hua
    Zhuang, Yun
    Sun, Hong-li
    Shen, Yun-feng
    CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (01) : 72 - 76
  • [45] Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors
    Alvarez-Reguera, Carmen
    Prieto-Pena, Diana
    Herrero-Morant, Alba
    Sanchez-Bilbao, Lara
    Batlle-Lopez, Ana
    Fernandez-Luis, Sara
    Paz-Gandiaga, Nerea
    Blanco, Ricardo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 123 : 102 - 106
  • [46] JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
    Santos, Fabio P. S.
    Verstovsek, Srdan
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (09) : 1098 - 1109
  • [47] Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients
    Besses, Carlos
    Alvarez-Larran, Alberto
    Martinez-Aviles, Luz
    Mojal, Sergi
    Longaron, Raquel
    Salar, Antonio
    Florensa, Lourdes
    Serrano, Sergi
    Bellosillo, Beatriz
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (04) : 413 - 419
  • [48] BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia
    Zhang, Yanqing
    Bi, Hailiang
    Wang, Ying
    Chen, Long
    Pan, Jiaqi
    Xu, Ping
    Wang, Wei
    Yang, Shaobin
    BLOOD SCIENCE, 2022, 4 (04): : 199 - 204
  • [49] JAK2 V617F Mutation in Adult Taiwanese Patients with Essential Thrombocythemia: More Prevalent in Old Patients and Correlated with Higher Hemoglobin Level and Higher Leukocyte Count
    Lin, Huan-Chau
    Chen, Caleb Gon-Shen
    Chang, Ming-Chih
    Wang, Wei-Ting
    Kao, Chen Wei
    Lo, An-Chi
    Su, Nai-Wen
    Chang, Yu-Cheng
    Chiang, Yi-Hao
    Chou, Kuei-Fang
    Liao, Po-Nien
    Cai, Guan-Jhe
    Cheng, Hung-I
    Lin, Johnson
    Chang, Yi-Fang
    Hsieh, Ruey-Kuen
    Lim, Ken-Hong
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2013, 7 (01) : 40 - 44
  • [50] Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari Syndrome without myeloproliferative neoplasm
    Helman, Ricardo
    Pereira, Welbert de O.
    Marti, Luciana C.
    Campregher, Paulo V.
    Puga, Renato Davi
    Hamerschlak, Nelson
    Chiattone, Carlos S.
    Santos, Fabio Pires de S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (03) : 443 - 445